Following admission of data fabrication by the first author, Anna Ahimastos, in a similar study of ramipril for patients with peripheral arterial disease (1), Baker IDI Heart and Diabetes Institute conducted an independent investigation of the trial, published in Annals in 2006 (2). Based on that investigation and our own analysis, we, the undersigned authors, wish to retract this article due to an inability to adequately validate primary data sources. Dr. Ahimastos maintains the integrity of the data and validity of reported results and has declined to answer additional questions. The investigation did not find culpability on our part, and we apologize unreservedly to the editors, reviewers, and readers of Annals of Internal Medicine. Given the clinical indications for ramipril and other angiotensin-converting enzyme inhibitors, we believe there is no risk that these possibly invalid trial data harmed trial participants or patients with peripheral arterial disease taking ramipril.